Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Insights - The company announced the acquisition of a 29.06% stake in PUMA SE for €1.5 billion, becoming the largest shareholder, which is expected to enhance its global competitiveness and support its "single focus, multi-brand, globalization" strategy [2] - The company anticipates steady growth in 2026, with projected net profits of 12.977 billion, 14.560 billion, and 15.822 billion yuan for 2025, 2026, and 2027 respectively, reflecting a slight downward adjustment from previous estimates [2] - The company remains optimistic about its core categories and channel reforms, with potential growth driven by the upcoming Paris Olympics and strong performance from its FILA brand [2] Financial Summary and Valuation Metrics - Revenue projections for the company are as follows: 62.356 billion yuan in 2023, 70.826 billion yuan in 2024, 78.234 billion yuan in 2025, 85.959 billion yuan in 2026, and 94.151 billion yuan in 2027, with year-over-year growth rates of 16.2%, 13.6%, 10.5%, 9.9%, and 9.5% respectively [5] - Net profit estimates are 10.236 billion yuan for 2023, 15.596 billion yuan for 2024, 12.977 billion yuan for 2025, 14.560 billion yuan for 2026, and 15.822 billion yuan for 2027, with a notable decline of 16.8% in 2025 [5] - The company's EPS (Earnings Per Share) is projected to be 3.6 yuan in 2023, 5.5 yuan in 2024, 4.6 yuan in 2025, 5.2 yuan in 2026, and 5.7 yuan in 2027, with corresponding P/E ratios of 19.0, 13.1, 15.7, 13.4, and 12.3 [5]

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1] Core Views - The company is expected to achieve a significant reduction in losses, with a projected net profit attributable to shareholders of -300 million to -240 million yuan for 2025, compared to -679.88 million yuan in 2024 [1] - The company is benefiting from the high demand for lithium iron phosphate (LFP) due to the recovery of profitability in the industry and increased demand for energy storage [1] - The company has a saturated order book and a production capacity utilization rate exceeding 95% [2] Financial Summary - The company forecasts a revenue of 3.645 billion yuan for 2025, a year-on-year increase of 141.2%, and expects to reach 5.825 billion yuan in 2026 and 9.745 billion yuan in 2027 [5] - The projected net profit for 2026 is 68 million yuan, and for 2027, it is 304 million yuan, indicating a strong recovery trajectory [5] - The gross margin is expected to improve from -11.1% in 2024 to 8.3% in 2026 and 8.7% in 2027 [8] Industry Insights - The lithium battery shipment in China is projected to reach 1875 GWh in 2025, a 53% year-on-year increase, with LFP battery shipments expected to grow by 130% [3] - The demand for LFP materials is also expected to rise, with shipments projected at 390 million tons in 2025, reflecting a 58% increase [3]

Investment Rating - The report does not explicitly state an investment rating for the company. Core Insights - Haisheng Medical is recognized as a national-level specialized and innovative "little giant" in the field of anesthesia and monitoring medical devices, with a comprehensive product offering and strong market presence in China [3][18]. - The company has a solid growth trajectory, with revenue expected to reach 304 million yuan in 2024, a slight decrease of 0.70% year-on-year, but showing positive growth in the first three quarters of 2025 with a revenue increase of 19.89% [3][12]. - The company has a robust technology matrix with 63 patents, including 13 invention patents, and has undertaken numerous significant technology projects at various governmental levels [3][18]. Company Overview - Haisheng Medical specializes in anesthesia and monitoring medical devices, serving major clinical departments such as anesthesia, ICU, and emergency [3][15]. - The company has established a strong brand and marketing network, with products used in over 600 top-tier hospitals, including prestigious institutions like Peking Union Medical College Hospital [5][12]. - The revenue composition for 2024 indicates that anesthesia products account for 52.60%, monitoring products for 36.59%, and surgical and nursing products for 10.47% [30][33]. Financial Performance - In 2024, the company is projected to achieve a gross margin of 52.09% and a net margin of 23.35% [12][30]. - The net profit attributable to the parent company for 2024 is expected to be approximately 70.92 million yuan, reflecting a year-on-year decline of 9.12% [12][30]. - The company’s R&D expenses for 2024 are estimated at 16.16 million yuan, representing 5.32% of revenue, with a year-on-year growth of 21.67% in the first three quarters of 2025 [5][12]. Industry Analysis - The medical device market in China is rapidly growing, with the market size expected to increase from 440.3 billion yuan in 2017 to 1.1544 trillion yuan by 2024, reflecting a compound annual growth rate (CAGR) of 14.76% [4][18]. - The low-value medical consumables market is projected to reach 185.2 billion yuan in 2024, with a year-on-year growth of 19.49% [4][30]. - The global medical device industry is also on an upward trend, with the market size expected to grow from 479.36 billion USD in 2023 to 637.96 billion USD by 2028 [4][18]. Competitive Position - Haisheng Medical's performance in terms of revenue growth is superior compared to its peers, with the company leading in revenue CAGR among comparable companies from 2022 to 2024 [12][14]. - The company has established a strong competitive edge through its proprietary technologies and extensive patent portfolio, which includes critical innovations in blood pressure sensors and bioelectrical signal acquisition [5][12].

有色金属/工业金属 江西铜业（600362.SH） 铜冶炼龙头再起航，资源并购助成长 投资评级：买入（首次） | 日期 | 2026/2/2 | | --- | --- | | 当前股价(元) | 57.08 | | 一年最高最低(元) | 70.70/19.01 | | 总市值(亿元) | 1,976.53 | | 流通市值(亿元) | 1,184.55 | | 总股本(亿股) | 34.63 | | 流通股本(亿股) | 20.75 | | 近 3 个月换手率(%) | 196.62 | 股价走势图 -80% 0% 80% 160% 240% 320% 2025-02 2025-06 2025-10 江西铜业 沪深300 数据来源：聚源 孙二春（分析师） 冯伟珉（联系人） sunerchun@kysec.cn 2026 年 02 月 03 日 fengweimin@kysec.cn 证书编号：S0790124070040 并购投资项目持续落地，铜业龙头再起航 江西铜业是国内领先的铜冶炼生产商，在铜以及相关有色金属领域建立了集勘 探、采矿、选矿、冶炼、加工的一体化产业链。目前公司主要资产包括国内规模 领先的 ...

北交所新股申购报告 海圣医疗（920166.BJ）：麻醉监护医疗器械小巨人，麻醉监护精准化矩阵驱动成长 北交所研究团队 ——北交所新股申购报告 | 诸海滨（分析师） | 车欣航（分析师） | | --- | --- | | zhuhaibin@kysec.cn | chexinhang@kysec.cn | | 证书编号：S0790522080007 | 证书编号：S0790525050001 | 海圣医疗：麻醉、监护类医疗器械细分领域国家级专精特新"小巨人" 海圣医疗是面向全球的麻醉、监护类医疗器械综合产品提供商，为国内该细分领 域头部企业，获评国家级专精特新"小巨人"、浙江省隐形冠军企业等。公司产 品广泛应用于麻醉科、ICU、急诊科等临床科室。技术研发上，截至 2025 年 6 月 30 日，公司已先后承担国家、省、市级重大科技项目十余项，已累计获国家 授权专利 63 项，其中发明专利 13 项。经营层面，2024 年公司营收 3.04 亿元， 同比微降 0.70%，归母净利润 7091.75 万元；2025 年前三季度营收、归母净利润 同比分别增长 19.89%、26.70%，增长态势向好。2024 年 ...

行 业 研 究 银行 2026 年 02 月 03 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -10% 0% 10% 19% 29% 2025-02 2025-06 2025-10 银行 沪深300 相关研究报告 《2026 年初银行存贷形势更新与展望 —行业深度报告》-2026.1.26 《规模高增&收益承压，"存款+基金" 成配置主线—理财登 2025 年报解读》 《企业信贷超季节性增长，信贷投放 前置趋势或延续 —行业点评报告》 -2026.1.16 2026 年净息差展望：筑底企稳 ——行业深度报告 刘呈祥（分析师） 朱晓云（分析师） liuchengxiang@kysec.cn 证书编号：S0790523060002 zhuxiaoyun@kysec.cn 证书编号：S0790524070010 理论估算 1.4%净息差支撑 6%左右的 RWA 增速 据我们测算，银行若保持 RWA 6%-7%的增速，理论净息差大约在 1.44%-1.57% 是底线水平，2025Q3 商业银行净息差为 1.42%，意味着银行资产扩张面临内生 资本补充的现实硬约束，"稳息差"仍然是 2026 年银行核心经 ...

- The report does not contain any quantitative models or factors for analysis[1][2][3]

税收收入同比转负，投资于人重要性凸显 固定收益研究团队 陈曦（分析师） 王帅中（联系人） chenxi2@kysec.cn 证书编号：S0790521100002 wangshuaizhong@kysec.cn 证书编号：S0790125070016 事件：财政部公布 2025 年 12 月财政数据，1-12 月全国一般公共预算收入同比下 降 1.7%（前值为+0.8%，下同），支出同比增长 1.0%（+1.4%）；1-12 月全国政府 性基金预算收入同比下降 7.0%（-4.9%），支出同比增长 11.3%（+13.7%）。 2026 年 02 月 02 日 ——2025 年 12 月财政数据点评 12 月财政数据的关注点 税收收入同比转负，非税收入降幅扩大。12 月税收收入同比下降 11.5%（+2.8%）， 同比转负，结束连续 8 个月的正增长，12 月企业所得税回落或为当月税收收入 增幅放缓的主要原因。12 月证券交易印花税同比下降 4.8%，增幅在 12 月权益市 场震荡调整与 2024 年同期基数回升影响下转负。非税收入降幅的扩大或因 2024 年一次性安排中央单位上缴专项收益抬高基数。 在投资于 ...

2026 年 02 月 02 日 券商金股解析月报（2026 年 02 月） 金融工程研究团队 苏俊豪（分析师） 证书编号：S0790522020001 胡亮勇（分析师） 证书编号：S0790522030001 王志豪（分析师） 证书编号：S0790522070003 魏建榕（首席分析师） 证书编号：S0790519120001 傅开波（分析师） 证书编号：S0790520090003 高 鹏（分析师） 证书编号：S0790520090002 盛少成（分析师） 证书编号：S0790523060003 蒋 韬（分析师） 证书编号：S0790525070001 相关研究报告 《开源量化评论（23）-"金股+"组 合的量化方案》-2021.4.26 《开源量化评论（32）-券商金股的内 部收益结构》-2021.8.29 魏建榕（分析师） 高鹏（分析师） weijianrong@kysec.cn 证书编号：S0790519120001 gaopeng@kysec.cn 证书编号：S0790520090002 2 月份券商金股特征解析 2 月份紫金矿业、中际旭创、海光信息、万华化学、贵州茅台、福斯特、山东黄 金等金股推 ...

2026 年 02 月 02 日 券商金股解析月报（2026 年 02 月） 金融工程研究团队 魏建榕（首席分析师） 证书编号：S0790519120001 傅开波（分析师） 证书编号：S0790520090003 高 鹏（分析师） 证书编号：S0790520090002 苏俊豪（分析师） 证书编号：S0790522020001 胡亮勇（分析师） 证书编号：S0790522030001 王志豪（分析师） 证书编号：S0790522070003 盛少成（分析师） 证书编号：S0790523060003 蒋 韬（分析师） 证书编号：S0790525070001 相关研究报告 《开源量化评论（23）-"金股+"组 合的量化方案》-2021.4.26 《开源量化评论（32）-券商金股的内 部收益结构》-2021.8.29 魏建榕（分析师） 高鹏（分析师） weijianrong@kysec.cn 证书编号：S0790519120001 gaopeng@kysec.cn 证书编号：S0790520090002 2 月份券商金股特征解析 2 月份紫金矿业、中际旭创、海光信息、万华化学、贵州茅台、福斯特、山东黄 金等金股推 ...